Twist Bioscience to Report Fiscal 2024 Fourth Quarter and Full Year Financial Results on Monday, November 18, 2024
24 Ottobre 2024 - 2:00PM
Business Wire
Company to host conference call at 8:00 AM
ET
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling
customers to succeed through its offering of high-quality synthetic
DNA using its silicon platform, today announced that it will issue
its financial results for the fiscal 2024 fourth quarter and full
year ended September 30, 2024, before the opening of the market on
November 18, 2024. The company plans to hold a conference call and
live audio webcast for analysts and investors at 8:00 a.m. Eastern
Time to discuss its financial results and provide an update on the
company’s business. The press release with the financial results
will be accessible from the company’s website prior to the
conference call through the Investor Relations section under the
“Company” tab at www.twistbioscience.com.
The conference call will be webcast live through the Investor
Relations section under the “Company” tab at
www.twistbioscience.com. Those parties interested in participating
via telephone must register on the Company’s Investor Relations
website or by clicking here. Upon registration, all telephone
participants will receive the dial-in number along with a unique
PIN number that can be used to access the call. To avoid delays, we
encourage participants to dial into the conference call fifteen
minutes ahead of the scheduled start time. The webcast replay will
be available for two weeks.
About Twist Bioscience Corporation
Twist Bioscience is a leading and rapidly growing synthetic
biology and genomics company that has developed a disruptive DNA
synthesis platform to industrialize the engineering of biology. The
core of the platform is a proprietary technology that pioneers a
new method of manufacturing synthetic DNA by “writing” DNA on a
silicon chip. Twist is leveraging its unique technology to
manufacture a broad range of synthetic DNA-based products,
including synthetic genes, tools for next-generation sequencing
(NGS) preparation, and antibody libraries for drug discovery and
development. Twist is also pursuing longer-term opportunities in
digital data storage in DNA and biologics drug discovery. Twist
makes products for use across many industries including healthcare,
industrial chemicals, agriculture and academic research.
Follow us on LinkedIn | X | YouTube | Instagram
View source
version on businesswire.com: https://www.businesswire.com/news/home/20241024652806/en/
For Investors: Angela Bitting SVP, Corporate Affairs
925-202-6211 abitting@twistbioscience.com
For Media: Amanda Houlihan Communications Manager
774-265-5334 ahoulihan@twistbioscience.com
Grafico Azioni Twist Bioscience (NASDAQ:TWST)
Storico
Da Dic 2024 a Gen 2025
Grafico Azioni Twist Bioscience (NASDAQ:TWST)
Storico
Da Gen 2024 a Gen 2025